ENDPOINTS

BridGene nets another Takeda deal amid plans to raise more funding and go public

Takeda must have liked what it got from the chemoproteomics work out of BridGene Biosciences. The Tokyo-based drugmaker announced Tuesday that it is once again enlisting the help of the startup, this time promising up ...

Feb 25, 2025 - 14:02
 0
BridGene nets another Takeda deal amid plans to raise more funding and go public
Takeda must have liked what it got from the chemoproteomics work out of BridGene Biosciences. The Tokyo-based drugmaker announced Tuesday that it is once again enlisting the help of the startup, this time promising up ...
Read More

Tags:

Previous Article

Endpoints' LGBTQ+ list: Nominate for 2025

Next Article

Reintroducing wolves to Yellowstone helped entire ecosystem thrive, 20-year stud...

Related Posts

Q4 earnings updates; Biogen details revised research strategy; RFK Jr. advances out of Senate committee; and more

Q4 earnings updates; Biogen details revised research st...

Feb 9, 2025  0

Teva launches Stelara biosimilar at 85% discount as wider field emerges

Teva launches Stelara biosimilar at 85% discount as wid...

Feb 21, 2025  0

Hunger-suppressing biotech Aardvark raises $94M in IPO

Hunger-suppressing biotech Aardvark raises $94M in IPO

Feb 13, 2025  0